home / stock / rvx:cc / rvx:cc news

RVX:CC News and Press, Resverlogix Corp. From 09/30/22

Stock Information
Company Name: Resverlogix Corp.
Stock Symbol: RVX:CC
Market: TSXC
Website: resverlogix.com
Menu
RVX:CC RVX:CC Quote RVX:CC Short RVX:CC News RVX:CC Articles RVX:CC Message Board
Get RVX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
RVX:CC - InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone's Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s future development related to COVID-19, will focus on the prevention and treatment of Post COVI...
RVX:CC - Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (P...

RVX:CC - Resverlogix Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “ Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent A...

RVX:CC - Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr. Norman Wong is retiring as CSO, effective today. “Dr. Kulikowski has a contributed t...
RVX:CC - Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders...

RVX:CC - Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “ Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulato...

RVX:CC - Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for a Type C meeting to review th...
RVX:CC - Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical ...

RVX:CC - Apabetalone's Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “ BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study ” in the prestigious American Journa...

Previous 10 Next 10